How The EU & UK’s Contrasting Approaches To AI Regulation Could Impact Pharma

From identifying novel drug targets to analyzing clinical trial data, artificial intelligence (AI) has a plethora of uses in pharmaceutical R&D. Due to its relative novelty, however, AI is largely unregulated across the globe – something that many major governments and policymakers have acknowledged as a potential problem.

While most experts agree that the dangers of AI must be somehow mitigated and monitored, there has been little consensus on how exactly this should be done. The EU and...